Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

234 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Magnetic resonance imaging in comparison to clinical palpation in assessing the response of breast cancer to epirubicin primary chemotherapy.
Bodini M, Berruti A, Bottini A, Allevi G, Fiorentino C, Brizzi MP, Bersiga A, Generali D, Volpi D, Marini U, Aguggini S, Tampellini M, Alquati P, Olivetti L, Dogliotti L. Bodini M, et al. Among authors: dogliotti l. Breast Cancer Res Treat. 2004 Jun;85(3):211-8. doi: 10.1023/B:BREA.0000025409.69516.23. Breast Cancer Res Treat. 2004. PMID: 15111758
Cytotoxic and antiproliferative activity of the CMF regimen administered in association with tamoxifen as primary chemotherapy in breast cancer patients.
Bottini A, Berruti A, Bersiga A, Brunelli A, Brizzi MP, Di Marco B, Cirillo F, Tampellini M, Bolsi G, Aguggini S, Betri E, Filippini L, Bertoli A, Alquati P, Dogliotti L. Bottini A, et al. Among authors: dogliotti l. Int J Oncol. 1998 Aug;13(2):385-90. doi: 10.3892/ijo.13.2.385. Int J Oncol. 1998. PMID: 9664137 Clinical Trial.
Accuracy of mammography and echography versus clinical palpation in the assessment of response to primary chemotherapy in breast cancer patients with operable disease.
Fiorentino C, Berruti A, Bottini A, Bodini M, Brizzi MP, Brunelli A, Marini U, Allevi G, Aguggini S, Tira A, Alquati P, Olivetti L, Dogliotti L. Fiorentino C, et al. Among authors: dogliotti l. Breast Cancer Res Treat. 2001 Sep;69(2):143-51. doi: 10.1023/a:1012277325168. Breast Cancer Res Treat. 2001. PMID: 11759820
Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: a single-institution phase III trial.
Bottini A, Berruti A, Brizzi MP, Bersiga A, Generali D, Allevi G, Aguggini S, Bolsi G, Bonardi S, Tondelli B, Vana F, Tampellini M, Alquati P, Dogliotti L. Bottini A, et al. Among authors: dogliotti l. Endocr Relat Cancer. 2005 Jun;12(2):383-92. doi: 10.1677/erc.1.00945. Endocr Relat Cancer. 2005. PMID: 15947110 Clinical Trial.
Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases.
Generali D, Dovio A, Tampellini M, Tucci M, Tedoldi S, Torta M, Bonardi S, Allevi G, Aguggini S, Milani M, Harris AL, Bottini A, Dogliotti L, Angeli A, Berruti A. Generali D, et al. Among authors: dogliotti l. Br J Cancer. 2008 Jun 3;98(11):1753-8. doi: 10.1038/sj.bjc.6604390. Epub 2008 May 27. Br J Cancer. 2008. PMID: 18506177 Free PMC article. Clinical Trial.
234 results